Refresh Tears
ApprovedSmall molecule
Refresh Tears is one of 33 small molecule programs targeting Retinopathy. It is currently in Approved.
1
Indications
4
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Retinopathy
#DrugCompanyPhaseTrials
1Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tricor
JJagotec
Approved
Lucentis
RochePhase 3
Betadine
BBecton, Dickinson and Company
Approved
Vabysmo
RochePhase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Inspra /eplerenone
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Skin1 trial
Treatment1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Refresh Tears. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- PPharmaceutical Research Network